1,2-dioctanoylglycerol (diC8)

functions as bioregulator of protein kinase C in human platelets
Also Known As:
diC8; 1,2-dicapryloylglycerol; 1,2-dioctanoyl-rac-glycerol; 1,2-dioctanoyl-sn-glycerol; 1,2-dioctanoylglycerol, (S)-isomer; dicaprylglyceride; sn-1,2-dioctanoylglycerol
Networked: 27 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results


1. Stapleton, Cliona M: 1 article (02/2010)
2. Kim, Yong-Sik: 1 article (02/2010)
3. Joo, Joung Hyuck: 1 article (02/2010)
4. Panettieri, Reynold A: 1 article (02/2010)
5. Jetten, Anton M: 1 article (02/2010)
6. Liao, Grace: 1 article (02/2010)
7. Steenbergen, Charles: 1 article (12/2005)
8. Yamamura, Ken: 1 article (12/2005)
9. Murphy, Elizabeth: 1 article (12/2005)
10. Katus, H A: 1 article (02/2001)

Related Diseases

1. Ischemia
12/01/2005 - "Using isolated adult rat ventricular myocytes, we found that addition of 1,2-dioctanoyl-sn-glycerol (DOG), to activate PKC under conditions that reduced myocyte death associated with simulated ischemia and reperfusion, also reduced SR Ca2+. Cell death was 57.9 +/- 2.9% and 47.3 +/- 1.8% in untreated and DOG-treated myocytes, respectively (P < 0.05). "
07/01/1998 - "Since diacylglycerol is the endogenous activator of PKC and as such might be expected cardioprotective, we have investigated whether: (i) the diacylglycerol analog 1,2-dioctanoyl-sn-glycerol (DOG) can protect against injury during ischemia and reperfusion; (ii) any effect is mediated via PKC activation; and (iii) the outcome is influenced by the time of administration. "
03/09/1998 - "The aim of this study was to investigate whether treatment with the protein kinase C (PKC) agonist 1,2-dioctanoyl-sn-glycerol (1,2DOG) can protect isolated adult Wistar rat cardiomyocytes against simulated ischemia and reoxygenation. "
08/18/2000 - "Before 20 minutes of global ischemia, Langendorff-perfused rat hearts were perfused for 20 minutes (control); preconditioned with 4 cycles of 5-minute ischemia and 5-minute reflow (PC); treated with either wortmannin (WM) or LY 294002 (LY), each of which is a PI3-kinase inhibitor, for 5 minutes before and throughout PC; treated with 1,2-dioctanoyl-sn-glycerol (DOG), an activator of PKC for 10 minutes (DOG); treated identically to the DOG group except with WM added 10 minutes before and during perfusion with DOG; or treated with either WM or LY for 25 minutes. "
2. Carcinoma (Carcinomatosis)
3. Thymoma (Thymic Carcinoma)
4. Neoplasms (Cancer)
5. Vesicular Stomatitis

Related Drugs and Biologics

1. Protein Kinase C
2. phorbol
3. Glycerol (Glycerine)
4. Platelet-Derived Growth Factor
5. 1,2-dioctanoylglycerol (diC8)
6. Phorbol 12,13-Dibutyrate
7. Tetradecanoylphorbol Acetate
8. Phorbol Esters
9. Calcium
10. 1-oleoyl-2-acetylglycerol